Feed BMEA
BM

Biomea Fusion, Inc.

BMEA · NASDAQ

$1.71 -0.29% (-$0.01)
1M +7.55%
Market Cap $123.6M
P/E Ratio -
Div. Yield -
ROE 171.19%

Bulios Fair Price

$1.33

22.2% downside

Current Price

$1.71

Undervalued Fair Value Overvalued

According to Bulios Fair Price, BMEA is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
0/9
Valuation
0 /100
Expensive
P/B 10.19x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining
Book val. growth 35.19%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor
ROIC 212.95%
Asset turnover 0.00x
ROE 171.19%
Debt
100 /100
Low
Debt/Equity 0.07x
Current ratio 3.47x
Int. coverage N/A
Stability
35 /100
Moderate
Beta -0.30x
Profitable years 0
EPS volatility 50.15%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about BMEA
Online

Sector

Healthcare

Industry

Biotechnology

CEO

Michael J. Hitchcock

Employees

37

Headquarters

San Carlos

Upcoming events

03 NOV

Earnings

Upcoming earnings report

42d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.